Parag Jain

Entrepreneur | Investor | Founder | AI Enabler Driving Business Impact

[Parag Jain @Parag__Jain]

The Biggest Constraint in Elder Care Isn't Hospitals.

→ It’s People. Caregivers.

Across many developed countries, long-term care facilities are facing growing staffing shortages.

Read more here 👉https://t.co/IIfUAWkec2

#ElderCare #Nursing

[Parag Jain @Parag__Jain]

@talok253 ITC - enough said! :)

[Parag Jain @Parag__Jain]

https://t.co/TG4R74IEGR

[Parag Jain @Parag__Jain]

https://t.co/hJghjURnuD

[Parag Jain @Parag__Jain]

Denta:
- Sandur Project in Karnataka (₹850 crore) is progressing well
- Jal Jeevan Mission & AMRUT continues to contribute meaningfully to revenue, with smooth fund flows
- Management aims to sustain high EBITDA margins of 30–35% thru technical efficiency & disciplined execution

[Parag Jain @Parag__Jain]

🚰 Water Infra Race | Denta vs EIEL vs VA Tech Wabag

📊 Denta & EIEL = domestic growth plays (high promoter holding, IPO entrants)
🌍 Wabag = global exposure with big Saudi desalination & sewage contracts

⚠️ Not SEBI registered. Edu purpose only.

#DentaWater #EIEL #VATechWabag

[Parag Jain @Parag__Jain]

Denta Water & Infra Solutions is showing strong momentum on the order and execution front. As per their latest investor con-call, FY26 order inflow guidance is ₹1,000 crore, with ₹180 crore already secured post-Q1 and an L1 position in a ₹120 crore tender. 🌊

[Parag Jain @Parag__Jain]

VA Tech Wabag’s international exposure is impressive - landing a 300 MLD desalination plant in Saudi Arabia (~₹2,332 Cr) and a 200 MLD sewage project in Riyadh (~₹3,251 Cr) really demonstrates their global capabilities.

Adds a strong diversification angle vs Denta or EIEL.

[Parag Jain @Parag__Jain]

💽 TSMC vs Intel – The Obvious King vs The Underdog

TSMC = clear leader, $280, priced for perfection 💡

Intel = underdog, $30, building US foundries, backed by gov + NVIDIA 🚀

✅ TSMC gives certainty
✅ Intel offers value

Your take?

#Semiconductors #Intel #TSMC #TechStocks

[Parag Jain @Parag__Jain]

Check out the latest article in my newsletter: How To Get PAID To Buy & Sell Stocks - Using Call and Put OPTIONS... https://t.co/hqqxWXqEg9 via @LinkedIn

[Parag Jain @Parag__Jain]

Check out the latest article in my newsletter: Contrarian Investing in the Age of AI https://t.co/OOUmn0paBs via @LinkedIn

[Parag Jain @Parag__Jain]

Check out the latest article in my newsletter: 🚀 Asset Allocation: The Difference Between Life-Changing Gains and Pocket Change https://t.co/NbNojCXqWC via @LinkedIn

[Parag Jain @Parag__Jain]

Check out the latest article in my newsletter: Google (Alphabet) at $154: A Common-Sense Investing Opportunity? https://t.co/dSQhzvIrrI via @LinkedIn

[Parag Jain @Parag__Jain]

Check out the latest article in my newsletter: 🛒 Stocks are on sale, but no one’s at the store - Are You? 🤔 https://t.co/bXAvCgsXzm via @LinkedIn

[Parag Jain @Parag__Jain]

Check out my latest article: Analysis of Morepen Laboratories' Q3 FY25 Earnings Concall Transcript https://t.co/jmGfk7BnCC via @LinkedIn

[Parag Jain @Parag__Jain]

I'm liking Natco Pharma as a long term play! Here are some positives:
1. CEO Rajeev is 2nd gen. promoter with skin in the game
2. CEO is aiming for jackpots than safer and low return route
3. -ve cards are out. +ve cards are laid and it's a matter of time b4 they materialise..

[ScoutQuest @scoutquest]

☎️ Con-call Highlights - #NatcoPharma Ltd

## Natco Pharma Q3 FY25 Earnings Call Key Takeaways:

**Financial Performance:**

* **Consolidated Revenue:** The company reported a total revenue of INR 6,511 million, comparing unfavorably with INR 7,956 million in Q3 FY24 and INR 14,349 million in Q2 FY25.
* **Revenue Composition:** Export formulations contributed to 44% of the total, domestic formulations to 15%, API to 10%, and other income (operating & non-operating) to 29%. Significant was the absence of revelemide sales in Q3 FY25.
* **Net Profit:** Dropped to INR 1,324 million from INR 2,127 million in the same quarter last fiscal year.
* **EBITDA:** Stood at INR 2,151 million, inclusive of other income.
* **EBITDA Margin:** Registered at 33%, which also includes other income.
* **Cash Reserves:** Cash and liquid investments were valued at INR 3,264 million as of December 31st, 2024.
* **Debt Levels:** Reported at INR 241 million, culminating in a net cash balance of approximately INR 3,000 million.
* **Dividend:** Announced a third interim dividend of INR 1.50 per equity share.

**Operational Performance:**

* **Export Formulation Business:** Q3 witnessed a decreased contribution, but the outlook for subsequent quarters remains positive.
* **R&D Expenses:** These remained elevated from the previous quarter, impacting performance.
* **Revelemide:** Previous allocations were depleted by September, leaving Q3 without sales. However, a fresh allocation covering 1/3rd of the market is now effective.
* **Ozempic (Semaglutide) Settlement:** Partnered with Mylan, settled a US patent dispute with Novo Nordisk. While the US launch date is confidential, an Indian launch is anticipated in 2026 upon necessary approvals.
* **Everysdi (Risdiplam) ANDA:** Submission has been made for shared first-to-file status.
* **Olanzapine (Weight Loss):** Settlement discussions are ongoing.

**Future Outlook:**

* **Revelemide:** Anticipated to resume sales in Q4 FY25, driven by the recent allocation and expected robust performance. However, unclear if Q4 sales will outmatch Q4 FY24.
* **Semaglutide:** Aiming for a March 2026 launch in India, contingent on regulatory sanctions, focusing primarily on the injectable version.
* **Risdiplam:** Litigation is at a nascent stage.
* **Acquisitions:** Active pursuit of acquisitions to enhance the ROW business and potential development in the US market, although specifics were not provided.
* **FY26 Outlook:** A dip in earnings is forecasted due to revelemide's patent conclusion. The scale of the impact will hinge on factors like price eroding and cost management strategies. The company remains optimistic about sustained long-term growth through new products, improved ROW market performance, and advancements in crop sciences.
* **Crop Sciences:** Aiming for breakeven in the upcoming year with an ambitious revenue target of INR 120-150 million.

**Concerns:**

* **Revelemide Dependence:** Heavy reliance on revelemide creates earnings fluctuations, exemplified by Q3 FY25 results.
* **FY26 Earnings Forecast:** Expect significant downturn following revelemide’s patent expiration, bringing uncertainties for stakeholders.
* **Acquisition Strategy:** Despite exploring acquisitions, successful execution remains pending, raising operational deployment questions.

**Additional Points:**

* **R&D Expenditure:** Continues to be governed by cash flow dynamics; expected outlay is 7-8% of net sales.
* **Buyback Policy:** Currently ruled out as the focus remains on acquisitions despite substantial cash holdings.
* **Volatility:** Emphasis on their business model, which targets large-scale gains, inherently generating earnings volatilities, a notion reiterated throughout the call.

In summary, Natco experienced weaker Q3 FY25 results, majorly impacted by absent revelemide sales. While optimism surrounds FY25's concluding quarter, the forthcoming patent expiry and acquisition uncertainties present a murky long-term outlook.

* Machine generated highlights, exercise diligence

⚡ AI powered update by https://t.co/GztB06W8bg

Check-out https://t.co/GztB06W8bg to receive WhatsApp updates faster than twitter/X.

[Parag Jain @Parag__Jain]

💥Multibaggers: The Secret to Life-Changing Wealth in the Stock Market💥
In this article, I dive deep into what makes a multi-bagger investment, how to identify these opportunities, and why they play a crucial role in wealth building.
https://t.co/NEok22rJ1f

[Parag Jain @Parag__Jain]

#AuroPharma #OptionSelling #OptionsWritting #CashSecuredPut

[Parag Jain @Parag__Jain]

🚀 Investing at a Discount? Yes, It's Possible!
Check out my latest article: Smart Investing: How to Buy Shares at a Discount https://t.co/fpmQQwttyB via @LinkedIn

[Parag Jain @Parag__Jain]

🚀 Investing at a Discount? Yes, It's Possible!
Check out my latest article: Smart Investing: How to Buy Shares at a Discount https://t.co/fpmQQwttyB via @LinkedIn

[Parag Jain @Parag__Jain]

Check out the latest article in my newsletter: Using Data for Personal Finance Decisions: A Masterclass on Fundamental Analysis https://t.co/2gVrXitx6d via @LinkedIn